LY6K Antibody is affinity chromatography purified via peptide column.
Immunogen
LY6K antibody was raised against an 18 amino acid synthetic peptide near the amino terminus of human LY6K. The immunogen is located within the first 50 amino acids of LY6K.
Ly6k
Reactivity: Human
ELISA, FACS
Host: Mouse
Monoclonal
750747
unconjugated
Application Notes
LY6K antibody can be used for detection of LY6K by Western blot at 1 - 2 μ,g/mL.
Antibody validated: Western Blot in human samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
LY6K Antibody is supplied in PBS containing 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C,4 °C
Storage Comment
LY6K antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
Ly6k
(Lymphocyte Antigen 6 Complex, Locus K (Ly6k))
LY6K antibody, CT97 antibody, HSJ001348 antibody, ly-6K antibody, 2410015A16Rik antibody, 3110035B01Rik antibody, mLy-6K antibody, lymphocyte antigen 6 family member K antibody, lymphocyte antigen 6 complex, locus K antibody, LY6K antibody, Ly6k antibody
Background
LY6K Antibody: The lymphocyte antigen 6 complex locus K (LY6K), a member of cancer-testis antigen was initially identified as a molecular marker for head-and-neck squamous cell carcinoma as well a breast cancer. LY6K is a GPI-anchored membrane protein that is specifically associated with germ cell marker TEX101 and is strongly observed in testis, but only weakly in other tissues. LY6K mRNA was found to be upregulated in numerous bladder cancers due to gene amplification. Furthermore, knockdown experiments using LY6K siRNA reduced cell growth, migration and invasion in bladder carcinoma cell lines, suggesting that LY6K contributes to bladder cancer development.